• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Thoracic cancer. >Comparison of Endostar continuous versus intermittent intravenous infusion in combination with first‐line chemotherapy in patients with advanced non‐small cell lung cancer
【24h】

Comparison of Endostar continuous versus intermittent intravenous infusion in combination with first‐line chemotherapy in patients with advanced non‐small cell lung cancer

机译：对先进非小细胞肺癌患者的初级化疗结合的胚胎连续与间歇性静脉内输注的比较

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Intravenous infusion of Endostar for three to four hours per day for 14?days reduces patient compliance and affects quality of life. Continuous intravenous infusion (CI) represents a novel method of administration; however, it is unclear whether it is effective and safe when compared to the traditional method. We retrospectively reviewed patients with advanced non-small cell lung cancer (NSCLC) administered CI (20 patients) or intermittent intravenous infusion (II, 49 patients) of Endostar combined with first-line chemotherapy. Three patients in the II group discontinued therapy because of adverse effects. Median progression-free survival was 6.0 months in the CI group and 3.8 months in the II group, with no significant difference (P = 0.1). The objective response and disease control rates were also similar in the CI and II groups (40.0 vs. 32.6%, P = 0.562; 65 vs. 69.6%, P = 0.714, respectively). CI of Endostar combined with first-line chemotherapy for advanced NSCLC had similar progression-free survival, objective response, and overall response rates as II, with tolerable adverse effects. ? 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
机译：每天静脉内输注endostar三至四小时，减少患者遵守，影响生活质量。连续静脉输注（CI）代表一种新的给药方法;然而，与传统方法相比，目前尚不清楚它是否有效和安全。我们回顾性地审查了患有先进的非小细胞肺癌（NSCLC）的患者施用CI（20名患者）或间歇性静脉注射（II，49名患者）的内皮抑制联合联合第一线化疗。 II组中的三名患者因不良反应而停止治疗。中位数的无进展生存率为CI组6.0个月，II集团3.8个月，没有显着差异（P = 0.1）。目标反应和疾病控制率在Ci和II基团中也相似（40.0与32.6％，p = 0.562; 65 vs.69.6％，P = 0.714）。 Endostar的CI与先进NSCLC的一线化疗相结合，具有类似的无进展生存，客观反应和II的总反应率，具有可耐受的不利影响。 ？ 2019年的作者。中国肺部肿瘤集团和约翰瓦里和儿子澳大利亚发表的胸癌

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号